The present disclosure relates to crystalline form of (S)-N-((S)-1-cyclohexyl-2-{(S)-2-[4-(4-fluoro-benzoyl)-thiazol-2-yl]-pyrrolidin-1-yl}-2-oxo-ethyl)-2-methylamino-propionamide, salts and hydrates thereof. This disclosure also relates to solid oral formulation of (S)-N-((S)-1-cyclohexyl-2-{(S)-2-[4-(4-fluoro-benzoyl)-thiazol-2-yl]-pyrrolidin-1-yl}-2-oxo-ethyl)-2-methylamino-propionamide, pharmaceutically acceptable salts, solvates (including hydrates) thereof, as well as methods of treatment using the same.本揭示係關於(S)-N-((S)-1-環己基-2-{(S)-2-[4-(4-氟-苯甲醯基)-噻唑-2-基]-吡咯啶-1-基}-2-側氧基(oxo)-乙基)-2-甲基胺基-丙醯胺、其鹽及水合物之晶型。本揭示亦關於(S)-N-((S)-1-環己基-2-{(S)-2-[4-(4-氟-苯甲醯基)-噻唑-2-基]-吡咯啶-1-基}-2-側氧基-乙基)-2-甲基胺基-丙醯胺、其醫藥上可接受之鹽、溶劑合物(包括水合物)之固體口服調配物，及利用彼等治療之方法。
